Human Vaccines & Immunotherapeutics最新文献_第10页

Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices. 带状疱疹疫苗接种：初级保健提供者的知识、态度和做法。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-04-18 DOI: 10.1080/21645515.2025.2488093

Nikita Stempniewicz, Eric Davenport, Jinyi Wang, Carolyn Sweeney

{"title":"Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices.","authors":"Nikita Stempniewicz, Eric Davenport, Jinyi Wang, Carolyn Sweeney","doi":"10.1080/21645515.2025.2488093","DOIUrl":"https://doi.org/10.1080/21645515.2025.2488093","url":null,"abstract":"Primary care providers (PCPs) play a key role in vaccine recommendations and uptake, but limited information exists about PCP knowledge, attitudes, and practices regarding herpes zoster (HZ) vaccination. Clinical trials have shown that recombinant zoster vaccine (RZV) significantly reduces the risk of developing HZ. Hence, RZV is recommended by the US Advisory Committee on Immunization Practices (ACIP) for adults aged ≥50 years and immunocompromised adults aged ≥19 years. However, RZV uptake varies across age groups, and is lower for adults aged 50-59 compared to those aged ≥60 years. Using a cross-sectional web-based survey, this study described provider knowledge of HZ risk factors, ACIP recommendations, attitudes toward HZ vaccination, and HZ vaccination practices/barriers. Among 301 licensed PCPs in the US, knowledge of HZ risk factors was high, but only 29% were fully aware of the ACIP recommendations. PCPs indicated that HZ vaccination was important for patients aged 50-59, 60-69, and ≥70 years, with importance increasing with advancing age. During a typical week, an average of 44% (standard deviation = 32%) of PCPs reported initiating a conversation about HZ vaccination among adults aged 50-59 years. Key perceived barriers to recommending HZ vaccines to adults were contraindications and insufficient time to assess risk factors, while perceived HZ vaccine administration challenges included patients' out-of-pocket costs and lack of motivation. Results suggest that PCPs may benefit from updated information about ACIP recommendations, while both patients and providers may benefit from streamlining the vaccination process and educational efforts focused on addressing perceived barriers.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2488093"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Magnitude and durability of ProC6C-AlOH/Matrix-M^tm vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial. ProC6C-AlOH/Matrix-Mtm疫苗在布基纳法索成人中诱导的疟疾传播阻断抗体的大小和持久性

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-04-10 DOI: 10.1080/21645515.2025.2488075

Mohammad Naghizadeh, Kazutoyo Miura, Ebenezer Addo Ofori, Carole Long, Issaka Sagara, Alfred B Tiono, Jordan Plieskatt, Michael Theisen

{"title":"Magnitude and durability of ProC6C-AlOH/Matrix-Mtm vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial.","authors":"Mohammad Naghizadeh, Kazutoyo Miura, Ebenezer Addo Ofori, Carole Long, Issaka Sagara, Alfred B Tiono, Jordan Plieskatt, Michael Theisen","doi":"10.1080/21645515.2025.2488075","DOIUrl":"https://doi.org/10.1080/21645515.2025.2488075","url":null,"abstract":"ProC6C is a multi-stage malaria vaccine designed to disrupt parasite transmission and prevent infection by incorporating three parasite proteins (Pfs230-Pro, Pfs48/45-6C, and CSP) in a single vaccine antigen. The Phase 1 clinical trial (PACTR202201848463189) conducted in Burkina Faso, showed ProC6C-AlOH/Matrix-M was safe, well tolerated, immunogenic and generated a functional antibody response to all three constituent antigens at the primary output (D70). As magnitude and durability are central to an efficacious malaria vaccine, analysis was expanded past the initial endpoint, to determine transmission-blocking antibodies (anti-Pfs230 and anti-Pfs48/45-6C) present through D180. Analysis of transmission-reducing activity (TRA) showed 7/20 samples remained biologically active at D180. To identify immune biomarkers for high levels of TRA, the Pfs48/45-6C IgG concentration (calculated relative to the transmission-blocking mAb TB31F) was compared among TRA positive and negative individuals. The magnitude of anti-Pfs48/45-6C IgG had an excellent predictive accuracy (area under the receiver operating curve [ROC AUC] >0.8) with a threshold of 8.7 μg/ml for significant TRA. Additionally, there was significant correlation of TRA and anti-Pfs48/45 epitope I IgG concentration but not significant correlation for anti-Pfs230-Pro IgG, suggesting that vaccine-induced anti-Pfs48/45-6C IgG is the main predictor of TRA. This finding was corroborated by the observation that complement had no effect on TRA in the standard membrane feeding assay (SMFA). Collectively, these efforts confirm the transmission-blocking attributes of ProC6C and suggest that an alternative dosing regimen be evaluated in future clinical trials to improve longevity of functional transmission-reducing antibodies.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2488075"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of a behavioral insights-informed digital campaign to increase HPV vaccination in Bangladesh. 在孟加拉国开展基于行为洞察的数字运动以增加HPV疫苗接种的成本效益。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-05-05 DOI: 10.1080/21645515.2025.2500264

Sohail Agha, Wu Zeng

{"title":"Cost-effectiveness of a behavioral insights-informed digital campaign to increase HPV vaccination in Bangladesh.","authors":"Sohail Agha, Wu Zeng","doi":"10.1080/21645515.2025.2500264","DOIUrl":"https://doi.org/10.1080/21645515.2025.2500264","url":null,"abstract":"Digital platforms like social media are increasingly used to promote vaccine uptake in low- and middle-income countries (LMICs), yet limited evidence exists on their economic value. This study estimates the cost-effectiveness of a behavioral insights-informed social media campaign designed to increase HPV vaccine uptake among adolescent girls ages 9-14 in Bangladesh. A static cost-effectiveness analysis was conducted from the health system perspective. Inputs included campaign delivery costs, vaccine procurement and distribution, and treatment costs averted through cervical cancer prevention. Disability-adjusted life years (DALYs) averted per vaccinated girl were modeled using global burden-of-disease parameters. Effectiveness estimates were drawn from a quasi-experimental evaluation of the campaign, which reported a 9.5 percentage-point increase in vaccine uptake in one study arm and a 5.3 percentage-point increase in another, relative to a control group. These findings were preceded by a posttest study in Dhaka Division, which showed a strong association between campaign exposure and vaccination behavior. The incremental cost per vaccinated girl was $6.02, and the cost per DALY averted - i.e. the Incremental Cost-Effectiveness Ratio (ICER) - was $39.57. This falls well below established cost-effectiveness thresholds, including 40% of GDP per capita, commonly applied in LMICs. The findings suggest that digital campaigns guided by behavioral insights can represent a highly cost-effective approach to addressing persistent immunization coverage gaps. These results support the integration of such strategies into national immunization programs, particularly in contexts where traditional outreach methods may face financial constraints.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2500264"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges. 提高mRNA疫苗领域主路径提取效率：一种利用中间专利、屏蔽起始和末端专利边缘的新方法。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/21645515.2025.2454078

Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang

{"title":"Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges.","authors":"Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang","doi":"10.1080/21645515.2025.2454078","DOIUrl":"10.1080/21645515.2025.2454078","url":null,"abstract":"mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454078"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is informed consent correctly obtained for vaccinations? 接种疫苗是否正确获得知情同意？

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-16 DOI: 10.1080/21645515.2025.2465116

Dhriti Jagadish, Nathaniel Mamo, Felicia Pasadyn, Arthur Caplan

{"title":"Is informed consent correctly obtained for vaccinations?","authors":"Dhriti Jagadish, Nathaniel Mamo, Felicia Pasadyn, Arthur Caplan","doi":"10.1080/21645515.2025.2465116","DOIUrl":"10.1080/21645515.2025.2465116","url":null,"abstract":"Informed consent is an integral tenet of medical ethics. However, the United States lacks a standardized consent process for immunizations, with states and private companies instead reliant on Vaccine Information Statements (VISs) introduced by the 1986 National Childhood Vaccine Injury Act. VISs, rather than being developed with patient autonomy in mind, were a response to excessive vaccine injury litigation and resulting vaccine supply shortages. VISs do not provide meaningful information disclosures, with its producer - the Centers for Disease Control and Prevention - itself admitting that VISs should not be mistaken for informed consent forms. In its content, the VIS is too complex in its readability, does not situate immunization in a public health context, and does not present all alternatives. VIS delivery is also inadequate, with limited time given for patients to digest vaccine information and no documentation required to ensure that VISs were presented at all. Simply put, VISs do little to spark deliberation and increase vaccine confidence. This article recommends minor improvements to VIS content, delivery, and accountability mechanisms to ensure distribution. The authors argue that these patient-provider moments - for patients to better understand their health, the threat of disease, and the weight of their contribution to the public - should not be squandered.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2465116"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unreliable information and fear: Barriers to vaccination among IBD patients in China. 不可靠的信息和恐惧：中国IBD患者接种疫苗的障碍

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-24 DOI: 10.1080/21645515.2024.2446071

Jingwen Liu, Zelin Yan, Wen Hu, Shuyan Li, Yan Chen

{"title":"Unreliable information and fear: Barriers to vaccination among IBD patients in China.","authors":"Jingwen Liu, Zelin Yan, Wen Hu, Shuyan Li, Yan Chen","doi":"10.1080/21645515.2024.2446071","DOIUrl":"10.1080/21645515.2024.2446071","url":null,"abstract":"Vaccination plays a crucial role in safeguarding individuals with inflammatory bowel disease (IBD) from potential epidemics. In light of the resurgence of COVID-19 in China, unvaccinated IBD patients are vulnerable to infection and potentially serious complications. The aim of this study is to assess the vaccination uptake and willingness among IBD patients, as well as to explore the factors influencing their decision to decline vaccination. An online questionnaire was distributed and analyzed. Bivariate analyses and logistic regression models were used to identify relevant factors. Two hundred and three patients from 243 non-vaccinated respondents were included in the analysis. A total of 167 (82.3%) respondents continued to decline vaccination, with individuals holding stable employment and higher family income displaying significantly lower intent (p < .05). The primary factors contributing to their hesitancy were misinformation and apprehension regarding potential side effects. Obtaining vaccine information from online sources, particularly text-based content, and apprehensions surrounding the adverse effects of COVID-19 vaccination were also found to significantly diminish willingness to receive the vaccine (p < .01). The present study revealed that unreliable information about vaccines is a key factor of hesitancy among non-vaccinated IBD patients. Making efforts to spread true information about the COVID-19 vaccine is of great importance.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2446071"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy. 免疫治疗时代食管胃交界HER2耐药与胃癌的机制探讨

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/21645515.2025.2459458

Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao

{"title":"Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy.","authors":"Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao","doi":"10.1080/21645515.2025.2459458","DOIUrl":"10.1080/21645515.2025.2459458","url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME). Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes. By integrating recent research findings and clinical trials, this review aims to provide oncologists and researchers with insights into developing more effective treatments for patients with drug-resistant HER2-positive G/GEJ cancer.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2459458"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season. 芬兰和德国在2023-24流感季节加强了标准剂量和高剂量流感疫苗的被动安全性监测。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-18 DOI: 10.1080/21645515.2025.2475616

Marina Amaral de Avila Machado, Sophie Gallo, Alexander Goldstein, Parth Vachhani, Reddappa Maniganahally Byrareddy, Anu Kantele, Hanna Välimaa, Jörg Schelling

{"title":"Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season.","authors":"Marina Amaral de Avila Machado, Sophie Gallo, Alexander Goldstein, Parth Vachhani, Reddappa Maniganahally Byrareddy, Anu Kantele, Hanna Välimaa, Jörg Schelling","doi":"10.1080/21645515.2025.2475616","DOIUrl":"10.1080/21645515.2025.2475616","url":null,"abstract":"Enhanced Passive Safety Surveillance was used to detect safety signals before the peak period of immunization with quadrivalent inactivated influenza vaccines (IIV4) in Finland (standard dose [SD]) and Germany (high dose [HD]) in the 2023-24 season. The primary objective was to evaluate adverse drug reactions (ADRs) occurring ≤7 days following IIV4 vaccination. Enrolled participants were vaccinated in routine clinical care settings and encouraged to report ADRs. Exposure data and ADR reports were collected in a near real-time manner using an electronic system. Vaccinee reporting rate (RR) with 95% confidence interval (CI) was calculated as the number of vaccinees reporting ≥ 1 ADR divided by total number of vaccinees. In Finland for SD-IIV4, among 1,003 vaccinees aged ≥ 6 months, 81 reported a total of 192 suspected ADRs occurring ≤ 7 days following vaccination (vaccinee RR 8.08%; 95% CI 6.46, 9.94). In Germany for HD-IIV4, among 1,075 vaccinees aged ≥ 60 years, 15 reported 46 ADRs that occurred in ≤ 7 days of vaccination (vaccinee RR 1.40%; 95% CI 0.78, 2.29). No safety signal was detected during this surveillance. The 2023-24 season surveillance did not suggest any clinically significant changes in safety profile compared with previously reported safety data for SD-IIV4 and HD-IIV4.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2475616"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human vaccines and immunotherapeutics: News March 2025. 人类疫苗和免疫疗法：新闻2025年3月。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-04-07 DOI: 10.1080/21645515.2025.2489257

Ronald Ellis, Adam Weiss

引用次数: 0

Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines. 对其他疫苗中使用的基孔肯雅疫苗平台的安全性进行总体审查。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-11 DOI: 10.1080/21645515.2025.2463191

Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker, Beate Kampmann, Katharina Stegelmann, Xu Xiong, Andy Stergachis, Flor M Munoz, Pierre Buekens, Agustina Mazzoni

{"title":"Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.","authors":"Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker, Beate Kampmann, Katharina Stegelmann, Xu Xiong, Andy Stergachis, Flor M Munoz, Pierre Buekens, Agustina Mazzoni","doi":"10.1080/21645515.2025.2463191","DOIUrl":"10.1080/21645515.2025.2463191","url":null,"abstract":"Chikungunya virus (CHIKV), transmitted through Aedes mosquitoes, is a significant global health concern. Various vaccine platforms have been explored to combat CHIKV, including formalin inactivation, live-attenuated strains, virus-like particles (VLPs), viral vectors, and mRNA technologies. This umbrella review synthesizes evidence on the safety profiles of vaccine platforms used in Chikungunya vaccines that have been applied in other vaccines, focusing on adverse events of special interest (AESI) in pregnant persons, children, and adolescents. A comprehensive overview of systematic reviews (SRs) was conducted. Results: Seven systematic reviews were included and complemented with primary studies. Vaccines like influenza, human papillomavirus (HPV), and COVID-19, which share platforms with Chikungunya vaccines, showed no significant increase in AESI. Moderate-to high-quality SRs supported favorable safety profiles. Vaccines sharing platforms with Chikungunya vaccines generally exhibit acceptable safety profiles in pregnant persons, children, and adolescents.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2463191"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0